Possibly a dumb question, but interested to know how the CPT 1 code process will run and when it will have an impact on sales.
I am aware the consideration for CPT 1 has been accepted. From what I know this means that SphygmoCor is being considered by AMA for CPT 1 code. It doesn't mean that it has it yet, so there is yet to be any benefit to sales(?)
The RUC is developing recommendations for fees from April then finalising these in November. I am not sure what the implication of this is for sales.
At what stage is the CPT 1 code usable by hospitals and practitioners? I seem to remember something about Jan 2016 in an investor presentation.
As a side note, I'm expecting a slow dwindle down to the low teens, at which stage I'm buying before we get more positive news.
CPT 1 Schedule
Add CDX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
12.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $35.30M | |||
| Open | High | Low | Value | Volume |
| 12.5¢ | 12.5¢ | 11.5¢ | $36.27K | 304.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 90295 | 11.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 12.0¢ | 264569 | 2 |
View Market Depth
| Last trade - 15.49pm 19/11/2024 (20 minute delay) ? |
| CDX (ASX) Chart |